Karyopharm Therapeutics (KPTI) Work In Process (2020 - 2025)

Karyopharm Therapeutics has reported Work In Process for 6 years, with the latest figure at $3.0 million in Q4 2025.

• For the quarter ending Q4 2025, Work In Process fell 15.87% year-over-year to $3.0 million; the trailing twelve-month figure through Dec 2025 stood at $3.0 million (down 15.87% YoY), and the FY2025 full-year result was $3.0 million, down 15.87% from the prior year.
• Work In Process for Q4 2025 stood at $3.0 million, up from $2.9 million in the prior quarter.
• The five-year high for Work In Process was $4.2 million in Q2 2025, with the low at $781000.0 in Q1 2021.
• Historically, Work In Process has averaged $2.3 million across 5 years, with a median of $1.9 million in 2021.
• Annual changes were most pronounced in 2021 — Work In Process jumped 193.34% — and 2023, when it plunged 40.68%.
• Karyopharm Therapeutics' Work In Process stood at $1.9 million in 2021, then decreased by 0.9% to $1.9 million in 2022, then fell by 7.77% to $1.7 million in 2023, then jumped by 104.5% to $3.5 million in 2024, then declined by 15.87% to $3.0 million in 2025.
• The last three Work In Process figures came in at $3.0 million (Q4 2025), $2.9 million (Q3 2025), and $4.2 million (Q2 2025), per Business Quant data.